Silver Spring, Maryland — The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding specific glucose monitoring systems after Abbott Diabetes Care recommended their removal from the market. This precaution comes in light of reports indicating the affected devices may provide inaccurate glucose readings, which could endanger individuals managing diabetes.
The alert primarily concerns certain models of the FreeStyle Libre 3 Sensor and FreeStyle Libre 3 Plus Sensor. Health officials have noted that these devices can misrepresent low glucose levels, potentially leading to improper treatment decisions. Importantly, no formal recall has been initiated.
According to the FDA, Abbott Diabetes Care has observed seven fatalities and approximately 736 serious injuries linked to these inaccuracies. This has prompted the agency to act swiftly, as erroneous glucose readings over a sustained period could significantly complicate diabetes management.
Consumers currently using these sensors are encouraged to check if their device is among those affected. If it is, Abbott will provide a complimentary replacement. Notably, the alert does not extend to the FreeStyle Libre 3 readers, accompanying mobile applications, or other related products.
The affected devices can be purchased through various channels, including the Abbott Diabetes Care website, Amazon Pharmacy, Walgreens, and medical supply retailers. The FDA’s Early Alerts serve to notify the public of potential health risks posed by medical devices that do not yet warrant an official recall.
For individuals reliant on glucose monitoring for their health, this alert underscores the importance of verifying the safety of their devices. Regular communication from healthcare providers and manufacturers will be essential in navigating this situation.